Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD07805/47 (brimonidine tartrate) 0.5% gel for flushing in rosacea
2013-005083-26Phase 2Completed
- Sponsor
- Galderma
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of brimonidine in Erythematotelangiectatic Rosacea (ETR) and papulopustular rosacea, sponsored by Galderma. Primary endpoint: Objective prevention of hot-water–induced flushing. Started Feb 2014; status: completed.
02
Drugs
brimonidine
03
Conditions
Erythematotelangiectatic Rosacea (ETR)papulopustular rosacea
Beyond the preview
Go deeper on 2013-005083-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005083-26.